POMALYST® (pomalidomide) homepage

This site is intended for US audiences only.

POMALYST is a prescription medicine, taken along with the medicine dexamethasone, used to treat adults with multiple myeloma who have previously received at least 2 medicines to treat multiple myeloma, including a proteasome inhibitor and lenalidomide, and whose disease has become worse during treatment or within 60 days of finishing the last treatment. It is not known if POMALYST is safe and effective in children.

The REMS Companion App

Easily access the POMALYST REMS® program.

Download now

Understanding relapsed
multiple myeloma

Hypothetical caregiver holding onto the shoulders of a POMALYST® (pomalidomide) patient with relapsed/refractory multiple myeloma
Hypothetical caregiver holding onto the shoulders of a POMALYST® (pomalidomide) patient with relapsed/refractory multiple myeloma

Why am I changing medications?

Your doctor may have told you that your multiple myeloma has come back, also known as a relapse. This means your multiple myeloma is no longer responding to the medications you’re taking.

For this reason, it may be time to change your treatment. POMALYST® (pomalidomide) is proven to help you fight disease progression after you have received REVLIMID® (lenalidomide) and a proteasome inhibitor.

POMALYST is taken in combination with one or two other medications.

Learn more about how POMALYST works here.

POMALYST is taken in combination with dexamethasone on days 1-21 of a 28-day cycle.

According to an analysis of the triplet regimen, POMALYST (pomalidomide) + low-dose dexamethasone + daratumumab. This
analysis includes both intravenous and subcutaneous formulations of daratumumab. Data collection time: August 2021-February 2022.

Relapsing multiple myeloma is a progressive, cyclical disease.

Over time, it’s common for a person with multiple myeloma to go through periods of response to treatment and periods of relapse. To find out how your disease is progressing, your doctor will monitor the levels of M protein in your blood. A large increase in this protein, or M spike, can indicate a relapse.

RESPONSE TO TREATMENT

If medication effectively treats multiple myeloma, M protein numbers tend to decrease and symptoms may improve.

RELAPSE

During a relapse, your M protein numbers may go back up. You may also experience new or worsening symptoms.

M SPIKE

An increase in M protein typically indicates your disease has returned after a period of response.

Why does multiple myeloma keep coming back?

Multiple myeloma is currently an incurable disease. Treatment can significantly reduce the number of myeloma cells. But these cells can stop responding to medication, which allows them to multiply uncontrollably. This is called a relapse, and starts the cycle of multiple myeloma once more.

Hypothetical POMALYST® (pomalidomide) patient with relapsed/refractory multiple myeloma sitting outdoors holding onto a glass of water
Hypothetical POMALYST® (pomalidomide) patient with relapsed/refractory multiple myeloma sitting outdoors holding onto a glass of water

This website is best viewed
using the horizontal display
on your tablet device.

This website is best viewed
using the vertical display
on your mobile device.